Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6228108 | 1.00 | HPGD (0.49) | HPGDRECQLEPHX1MAPTUSP2 | |
| SCHEMBL2201330 | 1.00 | HPGD (0.49) | HPGDRECQLEPHX1MAPTUSP2 | |
| SCHEMBL6224830 | 1.00 | HPGD (0.49) | HPGDRECQLEPHX1MAPTUSP2 | |
| SCHEMBL6252250 | 1.00 | HPGD (0.49) | HPGDRECQLEPHX1MAPTUSP2 | |
| SCHEMBL6253116 | 1.00 | HPGD (0.49) | HPGDRECQLEPHX1MAPTUSP2 | |
| SCHEMBL1339443 | 1.00 | HPGD (0.49) | HPGDRECQLEPHX1MAPTUSP2 | |
| SCHEMBL12280421 | 1.00 | HPGD (0.49) | HPGDRECQLEPHX1MAPTUSP2 | |
| SCHEMBL1339286 | 1.00 | HPGD (0.49) | HPGDRECQLEPHX1MAPTUSP2 | |
| SCHEMBL23886074 | 0.98 | HPGD (0.48) | HPGDRECQLEPHX1MAPTUSP2 | |
| Hydrochloric Acid SCHEMBL28504096 | 0.98 | HPGD (0.48) | HPGDRECQLEPHX1MAPTUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4736856-A2 | BICYCLIC AMINES AS CDK2 INHIBITORS | Incyte Corporation (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260070917-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | DIFFERENTIATED THERAPEUTICS INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260062426-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | DIFFERENTIATED THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4041731-B1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORP (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260022119-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION | 2026-01-22 | — | — | US | disclosed |
| EP-4673449-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | Differentiated Therapeutics Inc (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4665332-A2 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | Differentiated Therapeutics Inc (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12466828-B2 | Bicyclic amines as CDK2 inhibitors | INCYTE CORPORATION (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250243183-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION | 2025-07-31 | — | — | US | disclosed |
| US-12312331-B2 | Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors | INCYTE CORPORATION (US) | 2025-05-27 | — | — | US | disclosed |
| CN-116348458-A | Imidazolylpyrimidinylamine compounds as CDK2 inhibitors | 因赛特公司 | 2023-06-27 | — | — | CN | disclosed |
| US-20230024173-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION | 2023-01-26 | — | — | US | disclosed |
| CN-115298177-A | Bicyclic amines as CDK2 inhibitors | 因赛特公司 | 2022-11-04 | — | — | CN | disclosed |
| US-20220340579-A1 | PYRAZOLYL BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION | 2022-10-27 | — | — | US | disclosed |
| US-11472791-B2 | Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors | INCYTE CORPORATION (US) | 2022-10-18 | — | — | US | disclosed |
| EP-3288943-B1 | PYRROLO[2,3-B]PYRAZINYL ACRYLAMIDES AND EPOXIDES THEREOF AS INHIBITORS OF JANUS KINASE | PFIZER (US) | 2022-09-28 | — | — | EP | disclosed |
| US-11440914-B2 | Tricyclic amine compounds as CDK2 inhibitors | INCYTE CORPORATION (US) | 2022-09-13 | — | — | US | disclosed |
| US-11427567-B2 | Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors | INCYTE CORPORATION (US) | 2022-08-30 | — | — | US | disclosed |
| EP-4041731-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | Incyte Corporation (US) | 2022-08-17 | — | — | EP | disclosed |
| EP-2181996-A1 | Aminopiperidine derivatives | GLAXO GROUP LIMITED (GB) | 2010-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12312331-B2 | Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors | CDK2, CDK4, CDK2AP2 | HPGD 1173/4885RECQL 881/4885EPHX1 4223/4885 |
| US-20260022119-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | CCNA1, CDK1, CCNE1 | HPGD 2015/4885RECQL 1608/4885EPHX1 1861/4885 |
| US-11427567-B2 | Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors | CDK2, CDK4, CDK2AP2 | HPGD 1173/4885RECQL 881/4885EPHX1 4223/4885 |
| US-20220340579-A1 | PYRAZOLYL BICYCLIC AMINES AS CDK2 INHIBITORS | CDK2, CCNI, CDK1 | HPGD 713/4885RECQL 631/4885EPHX1 3397/4885 |
| US-20260062426-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | CCNA1, CCNE1, CCNA2 | HPGD 1854/4885RECQL 310/4885EPHX1 1499/4885 |
| US-20230024173-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | CDK2, CDK4, CDK2AP2 | HPGD 1173/4885RECQL 881/4885EPHX1 4223/4885 |
| US-20250243183-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | CDK2, CDK4, CDK2AP2 | HPGD 1173/4885RECQL 881/4885EPHX1 4223/4885 |
| US-11472791-B2 | Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors | CDK2, CDK2AP2, CDK4 | HPGD 1046/4885RECQL 1006/4885EPHX1 4025/4885 |
| US-11440914-B2 | Tricyclic amine compounds as CDK2 inhibitors | CDK2, CDK1, CCNI | HPGD 2003/4885RECQL 752/4885EPHX1 3626/4885 |
| US-20260070917-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | CDK2, CCNK, CCNC | HPGD 2055/4885RECQL 336/4885EPHX1 2412/4885 |
| US-12466828-B2 | Bicyclic amines as CDK2 inhibitors | CDK2, CDK1, CCNI | HPGD 1033/4885RECQL 757/4885EPHX1 3045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.